Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the resolutions passed at the 147th Ordinary General Meeting of Shareholders held on June 28, 2023. The filing covers matters reported on and resolved regarding the 146th fiscal year (April 1, 2022 to March 31, 2023).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. It confirms that the Consolidated Financial Statements for the 146th fiscal year were reported to shareholders, but the numerical data is not included in this document.
Material Changes and Resolutions
- Dividend Appropriation: The year-end dividend was approved at 90 yen (JPY90.00) per share.
- Director Elections: Eleven directors were elected. Christophe Weber, Andrew Plump, Costa Saroukos, Olivier Bohuon, Jean-Luc Butel, Ian Clark, Steven Gillis, John Maraganore, and Michel Orsinger were re-elected. Miki Tsusaka was newly elected. Masami Iijima was also re-elected.
- Director Bonuses: Approval was granted to pay bonuses totaling up to 400 million yen to three specific directors (excluding those residing overseas and External Directors) in office as of the end of the fiscal year.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risks, contingencies, or details on unusual items. The document is strictly a notice of shareholder meeting resolutions.
Investor Verification Checklist
- Verify the exact dividend payment date and record date for the approved 90 yen per share dividend.
- Review the full Consolidated Financial Statements for the 146th fiscal year to analyze revenue, profit, and cash flow figures not present in this summary.
- Confirm the specific allocation of the 400 million yen director bonus among the eligible directors.
- Check for any subsequent filings regarding the implementation of the new director appointments.